As the Zika virus spreads and concern grows about the world’s preparedness for outbreaks, GlaxoSmithKline Plc is proposing the creation of a unit dedicated to developing vaccines for diseases in markets offering little potential profit.
The London-based company is ready to provide a facility, staff and technology, and would welcome funding from the U.S., the U.K., the World Health Organization and other public entities, Ripley Ballou, Glaxo’s vice president of vaccines, said in a phone interview.
